Physician profile
Joy Curry Lockhart
NPI 1578089751
$906.87
in general payments reported to CMS, 2019-2025
13 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.99 · 2022: $54.96 · 2023: $64.13 · 2024: $391 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $457.64 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $135.07 | 2024-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $56.08 | 2022-2023 | |
| Glaxosmithkline, LLC. | $48.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $45.95 | 2024 | |
| Abbott Laboratories | $35.85 | 2023-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $29.05 | 2021-2024 | Wegovy |
| Supernus Pharmaceuticals, INC. | $22.20 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.18 | 2023 | |
| Hikma Pharmaceuticals USA | $15.72 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.01 | 2023 | Rexulti |
| Boston Scientific Corporation | $14.55 | 2024 | Ekosonic |
| Takeda Pharmaceuticals U.S.A., INC. | $12.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Lockhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.